Good Manufacturing Practices – A Regulatory Perspective Presented By: Ashok Kumar Dua Plant Head – Unichem Laboratories (Sikkim )

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

Geoffrey Levitt Chief Counsel, Regulatory and Research Building a Culture of Compliance and Risk Management August 26, 2005.
Introduction to the Supply Chain Risk Management Guide RPSGB, London 23 rd February 2010 Jill Jenkins - Pharmaceutical Quality Group.
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
World Health Organization
This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download, adapt, and distribute this.
Biomedical Auditing. The Biomedical Auditor works with medical devices, including in vitro diagnostics and biologics that are regulated as medical devices.
INSAG DEVELOPMENT OF A DOCUMENT ON HIGH LEVEL SAFETY RECOMMENDATIONS FOR NUCLEAR POWER Milestone Issues: Group C. Nuclear Safety. A. Alonso (INSAG Member)
Environmental Management Systems An Overview With Practical Applications.
Learning from GMP Inspections. Richard Bateman QA Specialist Pharmacist East and South East England Specialist Pharmacy Services.
INTERNAL AUDITS OF LABORATORIES Sanjay S Shetgar 1.
Corporate Ethics Compliance *
Personnel Basic Principles of GMP Workshop on
Top Tactics for Maximizing GMP Compliance in Blue Mountain RAM Jake Jacanin, Regional Sales Manager September 18, 2013.
Basic Research Administration Principles Presented by Ronald Kiguba Research Coordinator, Makerere Medical School.
Good Clinical Practice GCP
Health and Safety Executive Health and Safety Executive Discretion and Judgement: HSE’s approach Mike Cross 3 June 2014.
World Health Organization
Quality By Design - A Generic Industry Perspective
Regulatory Update Ellen Leinfuss SVP, Life Sciences.
ASEAN GMP TRAINING MODULE PERSONNEL
Project co-financed by European Union Project co- financed by Asean European Committee for Standardization Implementing Agency 1 Module 13 GMP Workshop.
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
1 ELEMENTS OF A 5(a)(2) OSHA STANDARD VIOLATION (Prima Facie) n The standard applies to the cited working conditions. n The terms of the standard were.
Fourth Annual Medical Research Summit Concurrent Session 4.05 – Managing CROs and SMOs from a Compliance Perspective Michael SwiatochaAprill 23, 2004.
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
3rd Party Audits and Regulatory Inspections Food Industry Perspective
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Tough Love: Understanding the Purpose and Processes of Quality Assurance.
Avoiding Noncompliance Lori F. Hirsch Managing Counsel July 10, 2013 a.
© 2011 Underwriters Laboratories Inc. All rights reserved. This document may not be reproduced or distributed without authorization. ASSET Safety Management.
PROTECT LEGAL AND REGULATORY REVIEW NOVEMBER 2014.
The Global Health Network Marijke Geldenhuys 19 September 2014 Adhering to the GCP Principles.. what does that even mean?
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
Important informations
ISO NON-CONFORMANCE, CORRECTIVE AND PREVENTIVE ACTION.
This class cannot be shared or copied without the written permission of PracticeWorks Systems, LLC.
Breach reporting to the REC Catherine Blewett, HRA Improvement & Liaison Manager.
Identifying Systemic Issues and Improving Customer Service Annette Donselaar ASM BA BCom MComLaw LLM DFP Grad Dip Compliance AACI Head of Australian Region.
Healthcare Commission update Sue Fraser-Betts Senior Assessment Manager October
Basic Principles of GMP
Reclaimed Wastewater Quality Criteria, Standards, and Guidelines
PhRMA Perspective on FDA Final Report FDA Advisory Committee on Pharmaceutical Sciences October 20, 2004 G.P. Migliaccio, Pfizer Inc.
Agenda for Session Compliance in Clinical Research
PROTECTION OF PERSONAL DATA. OECD GUIDELINES: BASIC PRINCIPLES OF NATIONAL APPLICATION Collection Limitation Principle There should be limits to the collection.
Office of Human Research Protection Georgia Health Sciences University.
Module 2Slide 1 of 26 WHO - EDM Quality Management Basic Principles of GMP Part One.
Basic Principles of GMP
Module 14Slide 1 of 23 WHO - EDM Basic Principles of GMP Active Pharmaceutical Ingredients Part Three, 18.
USDA Public Meeting; Control of E. coli O157:H7
SOLGM Wanaka Retreat Health and Safety at Work Act 2015 Ready? 4 February 2016 Samantha Turner Partner DDI: Mob:
Implementing the New EU General Data Protection Regulation Conference 2016 Preparing for a DP audit Ashley Roughton Nabarro LLP.
Revision N° 11ICAO Safety Management Systems (SMS) Course01/01/08 Module N° 9 – SMS operation.
Current risk and compliance priorities for law firms PETER SCOTT CONSULTING.
Good Manufacturing Practice (GMP) Compliance: GMPs EXPLAINED.
© Pharmaceutical Consultancy Services, All rights reserved. Quality System(s) Jaap Koster.
GMP Regulatory Perspective Dr. Pooja Mahadev Shirodkar Wallace Pharmaceuticals Pvt. Ltd. Date:
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
Hospital Accreditation Documentation Process & Standard Requirements
When things go wrong: reducing the risk of FCA enforcement action Birmingham 2016 Insurance and Financial Services Conference Wednesday, 18 June 2016 Jonathan.
Quality Management Checklist An essential guide to assist you, the quality expert, in enforcing the standards you expect on a daily basis across the whole.
GMP -Regulatory Perspective Sukanti Borkar Abbott India Ltd.
CPA Gilberto Rivera, VP Compliance and Operational Risk
Software Quality Control and Quality Assurance: Introduction
Current Plant Performance
ENTERPRISE RISK MANAGEMENT IN THE CASE OF THE FINANCIAL SERVICE SECTOR
Pharmaceutical Quality Control & current Good Manufacturing Practice
Pharmaceutical Quality in the 21st Century
POWER POINT PRESENTATION ON
Supervisory Control and Quality
The Insurance Brokers Code of Practice - an update
Presentation transcript:

Good Manufacturing Practices – A Regulatory Perspective Presented By: Ashok Kumar Dua Plant Head – Unichem Laboratories (Sikkim )

GMP – Good Manufacturing Practices. Till yesterday everything was fine !! But suddenly there is a problem in understanding of GMP in Indian Pharmaceutical Industry. Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What has gone wrong ? Are we not able to understand the concept of GMP now ? Something is really serious ? Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

Why it is happening ? The main reason is changed scenario of the industry Increased expectation from the Regulatory bodies Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

Why it is happening ? Increased regulatory oversight in the past year or two has forced quality, regulatory, and compliance personnel to be on their toes. One way that's a good thing in terms of ensuring Quality and, ultimately, protecting patients and end-users. However, it's not without its headaches - particularly when facing an increasingly demanding & inconsistent inspection environment. Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What we need to do now ? The key to inspection preparedness, however, is to cultivate a culture of quality within an organization rather than a culture of compliance We need to understand that a culture of quality is characterized by the mindset, "this is how our organization operates on a day-to-day basis under the confines of our quality management system," rather than approaching every day as if, "we're just trying to get ready for the next inspection." Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What we need to do now ? Beyond building a culture of quality, industry can more nimbly navigate the somewhat-volatile inspection process by being aware of patterns and trends that have emerged in recent months as part of increased oversight Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What are the emerging Trends ? Variation in investigator experience Heightened scrutiny of purchasing controls Elevated expectation of thoroughness and supporting documentation Increased emphasis on timeliness of responses and investigations Emerging focus on product in commercial distribution Mounting emphasis on management awareness Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What is the Trend in GMP C ompliance ? Increasing Number of Inspections Increasing numbers of Warning Letters Increasing Enforcement Penalties Increasing Harmonization between Regulatory Agencies Increasing use of Science & Technology Increasing use of subject matter expert Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What is the Top issue for C ompliance ? The top issue in the Warning Letters is the non- GMP compliant handling of electronic data or missing data integrity 8 warning letters contains the following comment in the same wording : Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What is the Top issue for C ompliance ? The top issue in the Warning Letters is the non- GMP compliant handling of electronic data or missing data integrity 8 warning letters contains the following comment in the same wording : Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What is the Top issue for C ompliance ? "Failure to prevent unauthorized access or changes to data and to provide adequate controls to prevent omission of data." "Failure of your quality unit to ensure that materials are appropriately tested and the results are reported.“ "Failure to adequately investigate complaints and extend the investigations to other batches that may have been affected." "Failure to have appropriate controls for issuance of batch records" "Failure to have appropriate documentation and record controls.” "Failure to record activities at the time they are performed and destruction of original records.”

What is the Top issue for C ompliance ? This selection of examples shows the lack of fundamental GMP principles which leads to a blatant misconduct of staff and ultimately to quality defects in the final product. The main responsibility usually has the quality unit, which task it actually would be to ensure a thorough training in production and quality control and to monitor compliance with the appropriate regulations. Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What is the Top issue for C ompliance ? These examples of non-GMP-compliant behavior are not limited to active ingredient manufacturers; there are very similar findings in Warning Letters issued to medicinal product manufacturers. Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

How do you feel about these trends and the impact on your work and your organization ? What will you do differently in your work as a result of knowing this trend ? Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What can be achieved by using trends ? Knowledge of GMP Trends can be used for developing, leading, managing and building GMP compliant work ethics and organizational culture for Quality. Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What can be achieved by using trends ? Knowledge of GMP compliance trends can be useful in pharmaceutical sectors to guide daily work, lead and manage operational control and to develop and execute strategic planning. Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What is your Perspective ? What is your opinion on 3-5 leading trends in GMP Compliance for Pharmaceuticals What is the value to you in knowing the regulatory compliance trends ? How can a small to medium scale company best use knowledge of the current trends ? Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What is the Global Perspective ? “ To learn and become better prepared for future inspections”. “ To hopefully prevent serious problems later on that would put us, or our customers at risk including the regulatory agencies that regulate us.” What are we doing to prevent this citation from being ours Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

What is the Global Perspective ? “ To learn and become better prepared for future inspections”. “ Put companies on alert to strengthen their SOPs – the way they are written and the way they are used to train personnel”. Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )

THANKS FOR LISTENING !! Ashok Kumar Dua – Plant Head Unichem Laboratories ( SIKKIM )